FOLH1 and neoplasm: Interestingly, [161Tb]Tb-PSMA-617 was found to have an enhanced therapeutic effect on PSMA(+) PC-3 PIP tumours with higher survival times among the mice when compared to its 177Lu counterpart (65 vs. 36 days).